BioVersys (IPO)

Funding Details
Awarder
Inbox
Date Award
May 18, 2025
Vertical
Biotechnology
Funding URL
View Funding Page
Valuation
$213,000,000

Company Info
Founding Year
2007
Traction
Strong investor support demonstrated by raising CHF 90 million through the IPO.
Organizations Involved
GSK
Founders
Marc Gitzinger
Company Description
BioVersys is a Basel-based biotech company focused on combating multidrug-resistant bacteria, developing key products such as BV100 for pneumonia and bloodstream infections, and alpibectir for tuberculosis in collaboration with GSK.
Market
Pharmaceuticals, specifically antimicrobial resistance treatments
Location
Basel, Switzerland

Links
Back to Home Back to Biotechnology Deals View Funding Announcement